Norbert Gleicher, Andrea Weghofer, David H. Barad

Slides:

Advertisements

Similar presentations

Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis Sesh Kamal Sunkara, Jyotsna Pundir,

Advertisements

Screening of sperm velocity by fluid mechanical characteristics of a cyclo-olefin polymer microfluidic sperm-sorting device Koji Matsuura, Mami Takenami,

Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C

Fresh and cryopreserved ovary transplantation and resting follicle recruitment Sherman Silber, Jorge Pineda, Kathleen Lenahan, Michael DeRosa, Jeffrey.

Protective effect of resveratrol against oxidative damage to ovarian reserve in female Sprague–Dawley rats Pınar Özcan, Cem Fıçıcıoğlu, Özge Kızılkale.

Abortion legislation: exploring perspectives of general practitioners and obstetrics and gynaecology clinicians Anastasia A. Theodosiou, Oliver R. Mitchell

Anastasia A. Theodosiou, Martin H. Johnson

Age at menarche: a predictor of diminished ovarian function?

External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients Scott M.

E. Jauniaux, I. Ben-Ami, R. Maymon Reproductive BioMedicine Online

Ovarian stimulation and intrauterine insemination in women aged 40years or more Amir Wiser, Einat Shalom-Paz, Shauna Leigh Reinblatt, Weon-Young Son,

Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction Antonio La Marca, Giovanni D’Ippolito

Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol Qi Yao, Yuanjiao Liang, Yong.

Intra-cycle fluctuations of anti-Müllerian hormone in normal women with a regular cycle: a re-analysis Annelies Overbeek, Frank J. Broekmans, Wouter.

E. Jauniaux, I. Ben-Ami, R. Maymon Reproductive BioMedicine Online

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH George Griesinger, Daniel B. Shapiro, Efstratios.

Anti-Müllerian hormone for the assessment of ovarian response in GnRH-antagonist- treated oocyte donors Nikolaos P. Polyzos, Dominic Stoop, Christophe.

A. La Marca, G. Sighinolfi, S. Giulini, M. Traglia, C. Argento, C

Amir Wiser, Einat Shalom-Paz, Jordana H

Gillian M. Lockwood Reproductive BioMedicine Online

Anti-Müllerian hormone as a predictor of pregnancy following IVF

Anti-Müllerian hormone as an independent predictor of twin versus singleton pregnancy in fresh cycles Reshef Tal, David B. Seifer, Moisey Khanimov, Eliana.

Sherman Silber Reproductive BioMedicine Online

Why are reproductive cancers more common in nulliparous women?

M.M. Francou, J. Ten, R. Bernabeu, J. De Juan

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

Utility of age-specific serum anti-Müllerian hormone concentrations

Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic Fernando de Mora, Bart C.J.M. Fauser Reproductive.

Sarah McCredie, William Ledger, Christos A. Venetis

Effect of N-acetyl-cysteine after ovarian drilling in clomiphene citrate-resistant PCOS women: a pilot study A. Nasr Reproductive BioMedicine Online

Do endometriomas grow during ovarian stimulation for assisted reproduction? A three- dimensional volume analysis before and after ovarian stimulation

Ovarian reserve determinations suggest new function of FMR1 (fragile X gene) in regulating ovarian ageing Norbert Gleicher, Andrea Weghofer, David H.

M. Dieterich, M. Bolz, T. Reimer, S. Costagliola, B. Gerber

Vitaly A. Kushnir, Jennifer Choi, Sarah K. Darmon, David F

Sequential use of letrozole and gonadotrophin in women with poor ovarian reserve: a randomized controlled trial Vivian Chi Yan Lee, Carina Chi Wai Chan,

Multifetal pregnancy reduction of triplets to twins compared with non-reduced triplets: a meta-analysis Yaniv Zipori, Jigal Haas, Howard Berger, Eran.

Cassandra’s prophecy: medic or mother

Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone Anne-Sophie Hamy, Raphaël Porcher, Caroline Cuvier, Sylvie Giacchetti, Marie-Hélène.

Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype C. Dechanet, C. Castelli,

Aneuploidy is a key causal factor of delays in blastulation: author response to ‘A cautionary note against aneuploidy risk assessment using time-lapse.

Follicular flushing in natural cycle IVF does not affect the luteal phase – a prospective controlled study M. von Wolff, A. Kohl Schwartz, P. Stute,

Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement John L.

Dehydroepiandrostendione sulphate and prediction of live birth after IVF in young women with low anti-Müllerian hormone concentration Miro Šimun Alebić,

A retrospective analysis of ovarian stimulation with letrozole in women undergoing artificial insemination by donor X.J. Sun, L. Jiang, L.C. Ji, R. Nie,

Influence of adjuvant chemotherapy on anti-Müllerian hormone in women below 35 years treated for early breast cancer Anne Perdrix, Mathilde Saint-Ghislain,

Serum anti-carbonic anhydrase I and II antibodies and idiopathic recurrent pregnancy loss S Caner Karahan, Suleyman Guven, Ahmet Mentese, Aynur Bacak,

LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles Kevin Doody, Paul Devroey, Keith Gordon, Han Witjes, Bernadette Mannaerts

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Stephen C. Collins, Esther Chan Reproductive BioMedicine Online

Ovarian stimulation and endometriosis progression or recurrence: a systematic review Edgardo Somigliana, Paola Viganò, Laura Benaglia, Andrea Busnelli,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Pietro Gambadauro, Ramesan Navaratnarajah

Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature Micah J. Hill, Gary Levy, Eric D. Levens

Jeff G. Wang, Nataki C. Douglas, Gary S. Nakhuda, Janet M

Cumulative success rates following mild IVF in unselected infertile patients: a 3-year, single-centre cohort study Daniel Bodri, Satoshi Kawachiya, Michaël.

Is parental consanguinity associated with reduced ovarian reserve?

Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies Anne-Sophie Hamy, Raphaël.

Nadine M. P. Daan, Annemieke Hoek, Eva Corpeleijn, Marinus J. C

Norbert Gleicher, Andrea Weghofer, David H. Barad

Predictive value of ovarian reserve markers in smoking and non-smoking women undergoing IVF Thomas Freour, Lionel Dessolle, Miguel Jean, Damien Masson,

Ovarian reserve screening before contraception?

Mariana M. Piccolomini, Mariana Nicolielo, Tatiana C. S

The significance of the number of CGG repeats and autoantibodies in premature ovarian failure Cem Fıçıcıoglu, Gazi Yildirim, Rukset Attar, Banu Kumbak,

GT Volpato, DC Damasceno, WG Kempinas, MVC Rudge, IMP Calderon

John Yovich, James Stanger, Peter Hinchliffe

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

M. Franz, J. Ott, A. Watrelot, L. Küssel, H. Husslein

Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve Norbert.

Use of progestins to inhibit spontaneous ovulation during ovarian stimulation: the beginning of a new era? Antonio La Marca, Martina Capuzzo Reproductive.

Presentation transcript:

Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation Norbert Gleicher, Andrea Weghofer, David H. Barad Reproductive BioMedicine Online Volume 21, Issue 3, Pages 360-365 (September 2010) DOI: 10.1016/j.rbmo.2010.04.006 Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions

Figure 1 Cross-sectional evaluation of anti-Müllerian hormone (AMH) concentrations in correlation to time from dehydroepiandrosterone (DHEA) initiation. The data are age stratified for under age 38 (blue) and ⩾38years (red). AMH concentrations improved over time significantly for the whole group (P=0.002). Age (P=0.007) and length of treatment (P=0.019) were independently associated with increasing AMH concentrations. Four outliers outside of range are not shown. This figure represents cross-sectional data, with every patient being represented only once, at time of first assessment. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Reproductive BioMedicine Online 2010 21, 360-365DOI: (10.1016/j.rbmo.2010.04.006) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions

Figure 2 Anti-Müllerian hormone (AMH) concentrations in individual patients in longitudinal follow up. This figure summarizes the progression in individual AMH concentrations between initial and follow-up evaluations. Mean±SD follow-up time was 155.8±119.1days; mean AMH was 0.31ng/ml; mean FSH was 18.0±17.2mIU/ml. All shown patients started with AMH <0.8ng/ml. Reproductive BioMedicine Online 2010 21, 360-365DOI: (10.1016/j.rbmo.2010.04.006) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions

Figure 3 Anti-Müllerian hormone (AMH) concentrations over time from DHEA initiation in women who did and did not conceive. The data are stratified by pregnancy achieved (red) or not achieved (blue). Interaction of pregnant versus non-pregnant, Wald chi-squared test 11.6; df=1; P=0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Reproductive BioMedicine Online 2010 21, 360-365DOI: (10.1016/j.rbmo.2010.04.006) Copyright © 2010 Reproductive Healthcare Ltd. Terms and Conditions